Patent SG-11201903601Q-A (SG)
Title: Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
Inventor: SATLIN ANDREW
IPC: A61K31/404
Filed: 2017-10-26
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111 0111010101111101111101 0 0111111111 11111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/081460 Al 03 May 2018 (03.05.2018) W I PO I PC T (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) (71) Applicants: SATLIN, Andrew [US/US]; 239 Central Park International Patent Classification: (74) Agent: MACALPINE, Jill, K.; Finnegan, Henderson, C07K 14/47 (2006.01) A61K 31/404 (2006.01) Farabow, Garrett & Dunner, LLP, 901 New York Avenue, C07K 16/18 (2006.01) A61K 39/395 (2006.01) NW, Washington, DC 20001 (US). International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/058587 kind of national protection available): AE, AG, AL, AM, International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 26 October 2017 (26.10.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/413,961 27 October 2016 (27.10.2016) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/415,165 31 October 2016 (31.10.2016) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: EISAI R&D MANAGEMENT CO., LTD. (84) Designated States (unless otherwise indicated, for every [JP/JP]; 6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo, kind of regional protection available): ARIPO (BW, GH, 112-8088 (JP). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, West #5C, New York, NY 10024 (US). FUKUSHIMA, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 5M, Tatsuto [JP/JP]; 1-3, Tokodai 5-chome, Tsukuba-shi, Ibara-TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ki, 300 2635 (JP). KM, ML, MR, NE, SN, TD, TG). — = = (54) Title: COMPOSITION FOR THE TREATMENT 0.25 - 0.20 - m 17'' 0 1 0 - 0 05 0 00 = INHIBITOR COMPRISING SOLUBLE OF AN Ar342 ALZHEIMER'S ANTI-ABETA PROTOFIBRIL ANTIBODY AND A BETA-SECRETASE DISEASE 300- 200- INSOLUBLE A1342 # BACE1 _ = = = A 0.15 = a 0 0 0 y # - • = . . A = _= : Methods disease ,1 Alzheimer's 0 methyl-4a,5,7,7a- \" pharmaceutically 7 1 1 er (S . S)N . 4 \ IZ.;) AN‘ oqb S L 4 C . ) p i p\ 4' .R 1' i ' 6) $ GO * * (# 6 ) J C) • 6 ) -i - 1 development of amino-5- and/or a 11 © oc © --- -- GC (57) tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-y1)-4- acceptable salt thereof (Compound X) are provided. Tg257.6 HETERO Tg2576 HETERO FIG. and combination therapies for treating, preventing, and/or delaying the onset and/or using an anti-A13 protofibril antibody (such as, for example, BAN2401 ) and N-[3-((4aS,5R,7aS)-2- fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide [Continued on next page] WO 2018/081460 Al MIDEDIMOMMIDEFIEHMOIDIEINIMOVOIS Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))